Form 4: PTC Therapeutics CFO Granted 20,000 RSUs, 50,000 Options

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, was granted 20,000 restricted stock units and 50,000 stock options on January 2, 2026.

Summary

• Pierre Gravier, Chief Financial Officer of PTC Therapeutics, Inc. (PTCT), received a grant of 20,000 restricted stock units (RSUs) on January 2, 2026.
• These RSUs will vest in four equal annual installments, with the first vesting occurring on January 2, 2027.
• Gravier also received a grant of 50,000 stock options on January 2, 2026, with an exercise price of $76.74.
• The stock options vest over four years, with 25% vesting on January 2, 2027, and an additional 6.25% of the original number of shares vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.
• Following these transactions, Gravier beneficially owns 92,449 shares of common stock and 50,000 stock options.
• The common stock beneficial ownership includes 272 shares and 257 shares acquired through the Issuer's employee stock purchase plan for periods ending June 30, 2025, and December 31, 2025, respectively.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the CFO is a positive signal for management alignment and retention. It indicates confidence in the company's future performance and provides long-term incentives. The use of a 10b5-1 plan adds transparency to the transaction.

Positives

• Grant of 20,000 restricted stock units (RSUs) to the Chief Financial Officer, aligning management interests with long-term shareholder value.
• Grant of 50,000 stock options to the Chief Financial Officer, providing a significant incentive for future performance and retention.
• The transactions were made under a Rule 10b5-1(c) plan, indicating pre-planned and transparent insider activity.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend through January 2, 2030, and January 1, 2036, respectively, indicating a long-term incentive structure for the Chief Financial Officer and a commitment to future performance.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industry, where equity grants like RSUs and stock options are commonly used to incentivize long-term performance and align executive interests with shareholder returns. The use of a 10b5-1 plan is also a common practice for insiders to manage their stock transactions in a compliant manner.

Comparison to Industry Standards

• The grant of RSUs and stock options to a Chief Financial Officer is a common practice in the biopharmaceutical sector, comparable to compensation structures seen at companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, which frequently utilize equity-based incentives to retain key talent and drive innovation.
• The vesting schedules, typically over three to five years, are also standard for ensuring long-term commitment and performance alignment within the industry.

Stakeholder Impact

• Shareholders: Increased alignment of the CFO's interests with long-term shareholder value through equity ownership and performance incentives.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• Management: Provides significant long-term incentives and compensation, aiding in retention and motivation of key personnel.

Next Steps

• Vesting of 25% of restricted stock units on January 2, 2027, with subsequent equal annual installments over the next three years.
• Vesting of 25% of stock options on January 2, 2027.
• Subsequent quarterly vesting of 6.25% of stock options beginning April 2, 2027, until fully vested.
• Potential exercise of stock options by January 1, 2036.

Key Dates

Recommendation

The filing reports routine equity grants to a key executive, which is a standard practice for executive compensation and aligns management incentives with long-term shareholder value. While positive for governance and retention, these grants alone do not fundamentally alter the company's operational or financial outlook to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider these grants as part of the ongoing compensation structure, while focusing on broader company performance and market conditions for investment decisions.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Pierre Gravier, CFO, Equity Grant, 10b5-1 Plan